(Q44836371)

6 December 2017

title

Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer (English)

1 reference

6 December 2017

1 reference

Matthew R Smith

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

6 December 2017

1 reference

6 December 2017

1 reference

6 December 2017

1 reference

6 December 2017

page(s)

742-745

1 reference

Testosterone Replacement Increases Fat-Free Mass and Muscle Size in Hypogonadal Men

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Fatigue in patients with prostate cancer receiving hormone therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Changes in body composition during androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Frailty in older adults: evidence for a phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Androgens and Erythropoiesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

Leuprolide with and without flutamide in advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.063

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2003.10.063

1 reference

6 December 2017

1 reference